Evidence map›Paper›PMID 23326540›Full record

ArticlePloS one2013

Fenretinide causes emphysema, which is prevented by sphingosine 1-phoshate.

Masanori Yasuo, Shiro Mizuno, Jeremy Allegood, Donatas Kraskauskas, Harm J Bogaard, Sarah Spiegel, Norbert F Voelkel

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. The role of dihydrosphingolipids in disease.Cellular and molecular life sciences : CMLS · 2019
    Review
  6. Article
  7. Article
  8. Article
  9. Sphingolipids as cell fate regulators in lung development and disease.Apoptosis : an international journal on programmed cell death · 2015
    Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 2 countries.

Masanori YasuoPulmonary and Critical Care Medicine Division and Victoria Johnson Center for Obstructive Lung Diseases, Virginia Commonwealth University, Richmond, Virginia, United States of America.
Shiro Mizuno
Jeremy Allegood
Donatas Kraskauskas
Harm J Bogaard
Sarah Spiegel
Norbert F Voelkel
Virginia Commonwealth University · US

Funding

NHLBI NIH HHS N01 HR046160NHLBI NIH HHS N01-HR-46160-3
6 · The paper itself

Abstract

Sphingolipids play a role in the development of emphysema and ceramide levels are increased in experimental models of emphysema; however, the mechanisms of ceramide-related pulmonary emphysema are not fully understood. Here we examine mechanisms of ceramide-induced pulmonary emphysema. Male Sprague-Dawley rats were treated with fenretinide (20 mg/kg BW), a synthetic derivative of retinoic acid that causes the formation of ceramide, and we postulated that the effects of fenretinide could be offset by administering sphingosine 1-phosphate (S1P) (100 µg/kg BW). Lung tissues were analyzed and mean alveolar airspace area, total length of the alveolar perimeter and the number of caspase-3 positive cells were measured. Hypoxia-inducible factor alpha (HIF-1α), vascular endothelial growth factor (VEGF) and other related proteins were analyzed by Western blot analysis. Immunohistochemical analysis of HIF-1α was also performed. Ceramide, dihydroceramide, S1P, and dihydro-S1P were measured by mass spectrometer. Chronic intraperitoneal injection of fenretinide increased the alveolar airspace surface area and increased the number of caspase-3 positive cells in rat lungs. Fenretinide also suppressed HIF-1α and VEGF protein expression in rat lungs. Concomitant injection of S1P prevented the decrease in the expression of HIF-1α, VEGF, histone deacetylase 2 (HDAC2), and nuclear factor (erythroid-derived 2)-like 2 (Nrf2) protein expression in the lungs. S1P injection also increased phosphorylated sphingosine kinase 1. Dihydroceramide was significantly increased by fenretinide injection and S1P treatment prevented the increase in dihydroceramide levels in rat lungs. These data support the concept that increased de novo ceramide production causes alveolar septal cell apoptosis and causes emphysema via suppressing HIF-1α. Concomitant treatment with S1P normalizes the ceramide-S1P balance in the rat lungs and increases HIF-1α protein expression via activation of sphingosine kinase 1; as a consequence, S1P salvages fenretinide induced emphysema in rat lungs.

Indexed as

AnimalsCaspase 3CeramidesEmphysemaFenretinideGene Expression RegulationHistone Deacetylase 2HumansHypoxia-Inducible Factor 1LysophospholipidsMaleNF-E2-Related Factor 2Phosphotransferases (Alcohol Group Acceptor)Protective AgentsPulmonary AlveoliRatsCaspase 3CeramidesFenretinideHdac2 protein, ratHistone Deacetylase 2Hypoxia-Inducible Factor 1LysophospholipidsNfe2l2 protein, ratNF-E2-Related Factor 2Phosphotransferases (Alcohol Group Acceptor)Protective AgentsSphingosinesphingosine 1-phosphateSphingosine KinaseVascular Endothelial Growth Factor Avascular endothelial growth factor A, rat

Identifiers

PMID23326540
PMCPMC3543313
OpenAlexW1989103647

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.